+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-05-07Number of Pages: 117

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

Global Meningococcal Vaccines Market: Snapshot

Meningococcal disease is caused by Neisseria meningitides, a gram-negative bacterium, and the majority of infections are caused by six serogroups out of many. The disease is mainly prevalent in infants, adolescents, and people suffering with risk of asplenia. The growing morbidity and mortality of meningococcal disease among vast populations has made it a global concern.

The incidence of invasive meningococcal disease varies with age, time, and geographic locations and can have endemic as well as epidemic affects. Usually triggered by environmental or immunogenic factors, the disease is best prevented by vaccinations. In recent years, the effective implementation of several targeted vaccination programs through massive campaigns in various countries, especially sub-Saharan Africa, has significantly reduced the burden of meningococcal disease. Technological advances in vaccinology has further improved their efficacy leading to key public health accomplishments.

Expanding at a CAGR of 12.40% during the period 2014–2022, the market for meningococcal vaccines is expected to reach a value of USD 4,450.4 million by 2022.

Combination Meningococcal Vaccines Gaining Prominence for Various Indications

Based on type, the meningococcal vaccines is majorly segmented into polysaccharide, conjugate, Men B and combination vaccines. Among these, polysacvcharide vaccines were the first vaccines to treat meningococcal disease. However, their use is declining due to their limitations to produce adequate immunologic memory response, possess meagre immunogenicity in infants, and are hypo-responsive when the doses are repeated. The combination vaccines segment is fast emerging as a prominent prevention modality as they overcome these drawbacks. Used in combination with other organisms such as Haemophilus influenzae type B, the use of combination vaccines is gaining traction across various regions. These vaccines are found to be especially helpful for the prevention of the disease in infants and toddlers.

Based on brand, polysaccharide vaccines are sub-segmented into NmVac4, Mencevax, Menomune, Bi Meningo, and Quadri Meningo. By brand, combination vaccines are further segmented into MenHibrix and Menitorix. Moreover, on the basis of brand, conjugate vaccines are sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, MenAfriVac, NmVac4-DT, and Menjugate.

Large Untapped Market in Asia Pacific to Offer Lucrative Growth Avenues

Geographically, the meningococcal vaccines market is segmented into Asia Pacific, North America, Europe, and Rest of the World (RoW). Of these, currently North America dominates the market and held the major revenue share in 2013. The substantial growth of this regional market is driven by a number of public awareness campaigns and infants’ immunization programs by governments. In addition, increased initiatives by several health protection agencies to recommend the vaccination of teens and preteens have boosted the demand for these vaccines in numerous countries.

Meanwhile, the Asia Pacific market is anticipated to grow at a significant pace. The impressive growth of the Asia Pacific market for meningococcal vaccines is primarily driven by rapid rise in populations prone to the disease incidence and the growing awareness of prevention methods.

Key market players operating in the meningococcal vaccines market include Biomed Pvt. Ltd., Baxter International Inc., Serum Institute of India Ltd., Pfizer Inc., Nuron Biotech, GlaxoSmithKline plc., Sanofi S.A., and Novartis International AG. 

 
Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, of which serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection. Meningococcal disease is a life threatening condition and potentially fatal illness caused due to the bacterium Neisseria meningitidis. It causes serious infection of the thin layers of connective tissue surrounding the brain and spinal cord called the meninges. Immunization by vaccines has been of great help to public health. It has saved millions of children and provided them with a chance of better and healthier life. Many diseases have been eradicated, while some have been better controlled. Thus vaccines are considered as the most powerful form of all preventive measures. Meningococcal disease is one such disease which has a high mortality rate if left undiagnosed and untreated. Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia and septicemia, caused due to N. meningitidis.
 
According to a report by CDC, incidences of bacterial meningitis have dropped by almost a third over the past decade due to stringent regulations, awareness and initiatives taken by the government as well as the citizens. The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate, and combination vaccines that are further segmented into different brands. The report also highlights and analyzes various brands of Men B vaccines recently approved, such as Bexsero and Trumenba, as well as the vaccine currently in pipeline - NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2012 to 2022. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2014 to 2022, while market size estimations have been made considering 2012 and 2013 as the base years. 
 
In terms of geographical distribution, the global meningococcal vaccines market has been classified into four major geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The regions are further broken down by major countries. The current and future market sizes (in terms of USD million) of the mentioned regional markets and their major countries have been provided in the report for the period 2012 to 2022 with their growth rate (%) for the period 2014 to 2022. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and flourish in the global meningococcal vaccines market. 
 
The global meningococcal vaccines market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of meningococcal vaccines industry. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the global meningococcal vaccines report, in order to give a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. The global meningococcal vaccines market report also covers qualitative information on certain areas in market overview section which include clinical features, epidemiology, diagnosis and treatment for meningococcal disease, types of meningococcal vaccines, and regulatory scenario. 
 
The report concludes with the company profiles section which includes key information about the major players in this market. Key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd.
 
The global meningococcal vaccines market is segmented as follow:
 
Meningococcal Vaccines Market, by Type
  • Polysaccharide Vaccines, by Brand
    • Menomune
    • Mencevax
    • NmVac4
    • Others
      • Quadri Meningo
      • Bi Meningo
  • Conjugate Vaccines, by Brand
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
    • NmVac4-DT
  • Combination Vaccines, by Brand
    • MenHibrix
    • Menitorix
  • Men B Vaccines, by Brand
    • Bexsero
    • Trumenba
Meningococcal Vaccines Market, by Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Africa
    • Rest of RoW


 
 
Back To Top